{"id":6668,"date":"2024-06-11T08:54:41","date_gmt":"2024-06-11T12:54:41","guid":{"rendered":"https:\/\/stg.gonaviance.com\/?p=6668"},"modified":"2024-06-11T08:54:41","modified_gmt":"2024-06-11T12:54:41","slug":"combination-urothelial-cancer-treatment-nearly-doubles-patient-survival-in-international-trial","status":"publish","type":"post","link":"https:\/\/stg.gonaviance.com\/es\/combination-urothelial-cancer-treatment-nearly-doubles-patient-survival-in-international-trial\/","title":{"rendered":"El tratamiento combinado del c\u00e1ncer urotelial casi duplica la supervivencia del paciente en un ensayo internacional"},"content":{"rendered":"<p>Un nuevo tratamiento combinado para el c\u00e1ncer urotelial casi duplic\u00f3 las tasas de supervivencia de los pacientes en un nuevo ensayo internacional. La combinaci\u00f3n de los f\u00e1rmacos anticancer\u00edgenos enfortumab vedotin y pembrolizumab (EV+P) produjo tasas de supervivencia significativamente mejores entre los pacientes con c\u00e1ncer urotelial avanzado (el tipo m\u00e1s com\u00fan de c\u00e1ncer de vejiga) en comparaci\u00f3n con la quimioterapia est\u00e1ndar, seg\u00fan los resultados de un gran ensayo cl\u00ednico internacional en el que participaron 185 sitios, incluyendo el <a href=\"https:\/\/www.hopkinsmedicine.org\/kimmel-cancer-center\" target=\"_blank\" rel=\"noopener\">Centro Oncol\u00f3gico Johns Hopkins Kimmel<\/a>\u2019s\u00a0<a href=\"https:\/\/www.hopkinsmedicine.org\/greenberg-bladder-cancer-institute\/\" target=\"_blank\" rel=\"noopener\">Instituto de C\u00e1ncer de Vejiga Greenberg<\/a>, en 25 pa\u00edses.<\/p>\n<h5 style=\"text-align: center;\"><span style=\"font-family: 'Gill Sans MT', 'Gill Sans', Calibri, sans-serif; font-size: 21px;\"> \u00a0<\/span><a href=\"https:\/\/www.hopkinsmedicine.org\/news\/newsroom\/news-releases\/2024\/03\/combination-urothelial-cancer-treatment-nearly-doubles-patient-survival-in-international-trial\" target=\"_blank\" rel=\"noopener\">LEER AQU\u00cd<\/a><\/h5>","protected":false},"excerpt":{"rendered":"<p>A new combination treatment for urothelial cancer nearly doubled patient survival rates in a new international trial. Combining [&hellip;]<\/p>\n","protected":false},"author":102,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"class_list":["post-6668","post","type-post","status-publish","format-standard","hentry","category-news","cancer-type-bladder","cancer-type-urethra","role-caregiver","role-person-with-cancer","post-cat-search-driven","media-type-text"],"acf":[],"_links":{"self":[{"href":"https:\/\/stg.gonaviance.com\/es\/wp-json\/wp\/v2\/posts\/6668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg.gonaviance.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg.gonaviance.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg.gonaviance.com\/es\/wp-json\/wp\/v2\/users\/102"}],"replies":[{"embeddable":true,"href":"https:\/\/stg.gonaviance.com\/es\/wp-json\/wp\/v2\/comments?post=6668"}],"version-history":[{"count":0,"href":"https:\/\/stg.gonaviance.com\/es\/wp-json\/wp\/v2\/posts\/6668\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg.gonaviance.com\/es\/wp-json\/wp\/v2\/media?parent=6668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg.gonaviance.com\/es\/wp-json\/wp\/v2\/categories?post=6668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}